Next Article in Journal
Investigating Diet as the Source of Tetrodotoxin in Pleurobranchaea maculata
Next Article in Special Issue
Antimicrobial Activity of the Marine Alkaloids, Clathrodin and Oroidin, and Their Synthetic Analogues
Previous Article in Journal
Bone Regeneration of Rat Tibial Defect by Zinc-Tricalcium Phosphate (Zn-TCP) Synthesized from Porous Foraminifera Carbonate Macrospheres
Article Menu

Export Article

Open AccessArticle

Synthesis and Neuroprotective Action of Xyloketal Derivatives in Parkinson’s Disease Models

School of Chemistry & Chemical Engineering, Sun Yat-Sen University, No. 135 Xingangxi Road, Guangzhou 510275, China
Department of Neurology, The First Affiliated Hospital, Sun Yat-Sen University, No. 58 Zhongshan Road II, Guangzhou 510080, China
Authors to whom correspondence should be addressed.
Mar. Drugs 2013, 11(12), 5159-5189;
Received: 1 November 2013 / Revised: 2 December 2013 / Accepted: 4 December 2013 / Published: 18 December 2013
PDF [1444 KB, uploaded 24 February 2015]


Parkinson’s disease (PD) is the second most common neurodegenerative disease affecting people over age 55. Oxidative stress actively participates in the dopaminergic (DA) neuron degeneration of PD. Xyloketals are a series of natural compounds from marine mangrove fungus strain No. 2508 that have been reported to protect against neurotoxicity through their antioxidant properties. However, their protection versus 1-methyl-4-phenylpyridinium (MPP+)-induced neurotoxicity is only modest, and appropriate structural modifications are necessary to discover better candidates for treating PD. In this work, we designed and synthesized 39 novel xyloketal derivatives (139) in addition to the previously reported compound, xyloketal B. The neuroprotective activities of all 40 compounds were evaluated in vivo via respiratory burst assays and longevity-extending assays. During the zebrafish respiratory burst assay, compounds 1, 9, 23, 24, 36 and 39 strongly attenuated reactive oxygen species (ROS) generation at 50 μM. In the Caenorhabditis elegans longevity-extending assay, compounds 1, 8, 15, 16 and 36 significantly extended the survival rates (p < 0.005 vs. dimethyl sulfoxide (DMSO)). A total of 15 compounds were tested for the treatment of Parkinson’s disease using the MPP+-induced C. elegans model, and compounds 1 and 8 exhibited the highest activities (p < 0.005 vs. MPP+). In the MPP+-induced C57BL/6 mouse PD model, 40 mg/kg of 1 and 8 protected against MPP+-induced dopaminergic neurodegeneration and increased the number of DA neurons from 53% for the MPP+ group to 78% and 74%, respectively (p < 0.001 vs. MPP+ group). Thus, these derivatives are novel candidates for the treatment of PD. View Full-Text
Keywords: xyloketal; Caenorhabditis elegans; zebrafish; C57BL/6; Parkinson’s disease xyloketal; Caenorhabditis elegans; zebrafish; C57BL/6; Parkinson’s disease

Figure 1

This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Supplementary material


Share & Cite This Article

MDPI and ACS Style

Li, S.; Shen, C.; Guo, W.; Zhang, X.; Liu, S.; Liang, F.; Xu, Z.; Pei, Z.; Song, H.; Qiu, L.; Lin, Y.; Pang, J. Synthesis and Neuroprotective Action of Xyloketal Derivatives in Parkinson’s Disease Models. Mar. Drugs 2013, 11, 5159-5189.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Mar. Drugs EISSN 1660-3397 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top